MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1681/asn.2016040449

Медицинская библиотека · Journal of the American Society of Nephrology : JASN · 2016

Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up.

Dahan Karine, Debiec Hanna, Plaisier Emmanuelle, Cachanado Marine, Rousseau Alexandra, Wakselman Laura, Michel Pierre-Antoine, Mihout Fabrice, Dussol Bertrand, Matignon Marie, Mousson Christiane, Simon Tabassome, Ronco Pierre, GEMRITUX Study Group

СтатьяМногоцентровое исследованиеРандомизированное исследованиеПеревод в очереди

Аннотация

Randomized trials of rituximab in primary membranous nephropathy (PMN) have not been conducted. We undertook a multicenter, randomized, controlled trial at 31 French hospitals (NCT01508468). Patients with biopsy-proven PMN and nephrotic syndrome after 6 months of nonimmunosuppressive antiproteinuric treatment (NIAT) were randomly assigned to 6-month therapy with NIAT and 375 mg/m2 intravenous rituximab on days 1 and 8 (n=37) or NIAT alone (n=38). Median times to last follow-up were 17.0 (interquartile range, 12.5-24.0) months and 17.0 (interquartile range, 13.0-23.0) months in NIAT-rituximab and NIAT groups, respectively. Primary outcome was a combined end point of complete or partial remission of proteinuria at 6 months. At month 6, 13 (35.1%; 95% confidence interval [95% CI], 19.7 to 50.5) patients in the NIAT-rituximab group and eight (21.1%; 95% CI, 8.1 to 34.0) patients in the NIAT group achieved remission (P=0.21). Rates of antiphospholipase A2 receptor antibody (anti-PLA2R-Ab) depletion in NIAT-rituximab and NIAT groups were 14 of 25 (56%) and one of 23 (4.3%) patients at month 3 (P<0.001) and 13 of 26 (50%) and three of 25 (12%) patients at month 6 (P=0.004), respectively. Eight serious adverse events occurred in each group. During the observational phase, remission rates before change of assigned treatment were 24 of 37 (64.9%) and 13 of 38 (34.2%) patients in NIAT-rituximab and NIAT groups, respectively (P<0.01). Positive effect of rituximab on proteinuria remission occurred after 6 months. These data suggest that PLA2R-Ab levels are early markers of rituximab effect and that addition of rituximab to NIAT does not affect safety.

Для цитирования: Dahan Karine, Debiec Hanna, Plaisier Emmanuelle, Cachanado Marine, Rousseau Alexandra, Wakselman Laura, Michel Pierre-Antoine, Mihout Fabrice, Dussol Bertrand, Matignon Marie, Mousson Christiane, Simon Tabassome, Ronco Pierre, GEMRITUX Study Group. Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up.. Journal of the American Society of Nephrology : JASN. 2016. DOI: 10.1681/asn.2016040449.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.